Kiran Mazumdar Shaw - Evolving Product Portfolio
  • Gaurav Sarkar
  • Apr 26 2013

Biocon had yet another stellar quarter. The pharma major delivered a strong performance driven by an evolving product portfolio and research services.Biocon CMD Kiran Mazumdar-Shaw said, "Our research services business performed well in Q4 and branded formulations revenues have also jumped 34%."